Global Quadriplegia Treatment Market Is Booming With Increasing Incidences Of Spinal Cord Injuries

The global quadriplegia treatment market is projected to grow with a compound annual growth rate (CAGR) of approximately 4.2 percent during the forecast period. It's easy to overlook the importance of mobility. However, for some unfortunate patients, movement is a distant memory. The loss of motor and sensory function of the trunk, arms, hands, legs, and pelvic organs is known as quadriplegia. This implies that the patient may not only be unable to move but that other vital physiological functions may be harmed or lost totally. Quadriplegia, of course, has a considerable impact on one's quality of life. Exorbitant medical and care costs are also an effect.

An increase in the number of spinal cord injuries primarily contributes to the rapid need for quadriplegia treatment, thereby driving global quadriplegia treatment growth. According to spinalcure.org, the number of instances of spinal cord injury in the elderly population is expected to rise by 2022. Around 20,800 persons in Australia have difficulties with their spinal cord. The World Health Organization also reported nearly 500,000 people around the world suffered from spinal cord injuries. Along with that, the market for quadriplegia therapy is growing due to an increase in the number of incidents of traffic accidents. In addition, as R&D efforts and technical breakthroughs in the field of quadriplegia improve, the acceptance and demand for quadriplegia treatment are expected to rise throughout the projection period. However, the market's expansion would be hampered by high treatment costs throughout the projection period.

The global quadriplegia treatment market is bifurcated into treatment type, distribution channel, route of administration, and region. Based on the treatment type, the global market is divided into corticosteroids, antibiotics, antispasmodics & muscle relaxants, narcotic analgesics, anticonvulsants, antidepressants, and non-steroidal anti-inflammatory drugs (NSAIDs). The distribution channel segment consists of online stores, drug stores, retail pharmacies, and hospital pharmacies. By route of administration, the market is classified into intravenous, oral, and others.

North America is expected to see the major share in the global quadriplegia treatment market throughout the projection period, owing to the region's high yearly medical costs for treating acute spinal cord injuries. The major revenue flow is expected from the US market owing to the well-developed healthcare infrastructure, presence of key market players, and high spending power of the population. Furthermore, on the back of higher healthcare spending and an increasing number of research institutions working toward the management & therapy of neurological illnesses in the region, the market in Europe is expected to gain a considerable share during the projected period. Asia Pacific on the other hand is projected to offer better growth opportunities for the market expansion. This is primarily due to increasing cases of spinal injuries, a large patient pool, increasing investments in healthcare infrastructures, and the rapid adoption of advanced medical technologies. All these factors are expected to contribute to the rapid growth of the market.

Major players functioning in the global quadriplegia treatment market include GlaxoSmithKline, Hoffmann La Roche, Zydus Cadila, Baxter International, Sanofi Pharmaceuticals, Merck & Co., Eli Lily & Co., Bristol Myers Squibb Co., Johnson & Johnson, Cipla, and AstraZeneca.

Recent Developments:

• In August 2021, Roche introduced an oral therapy for adults and children with Spinal Muscular Atrophy (SMA) (SMA). It's called Evrysdi, and it's the first and only medication for SMA patients in India.
• In August 2021, Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) received Fast Track Designation for MT-3921 for the treatment of spinal cord injury from FDA.

Browse the full “Quadriplegia Treatment Market By Treatment Type (Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antidepressants, Anticonvulsants, Narcotic Analgesics, Antispasmodics & Muscle Relaxants, And Antibiotics), By Route Of Administration (Oral, Intravenous, And Others), By Distribution Channel (Online Stores, Drug Stores, Retail Pharmacies, And Hospital Pharmacies), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/quadriplegia-treatment-market

Global quadriplegia treatment market is segmented as follows:

By Treatment Type

• Corticosteroids
• Non- Steroidal Anti-inflammatory Drugs (NSAIDs)
• Antidepressants
• Anticonvulsants
• Narcotic Analgesics
• Antispasmodics & Muscle Relaxants
• Antibiotics

By Route of Administration

• Oral
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Stores

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com